Vivek Subbiah

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures
    Vivek Subbiah
    Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    PLoS ONE 6:e18424. 2011
  2. doi request reprint Adolescent oncology: who cares?-the new KID on the block
    Vivek Subbiah
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 87, Houston, TX 77030, USA
    Support Care Cancer 18:771-3. 2010
  3. pmc Gastric adenocarcinoma in children and adolescents
    Vivek Subbiah
    The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Pediatr Blood Cancer 57:524-7. 2011
  4. pmc Ewing's sarcoma: overcoming the therapeutic plateau
    Vivek Subbiah
    Department of Investigational Cancer Therapeutics and Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA
    Discov Med 13:405-15. 2012
  5. pmc Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases
    Vivek Subbiah
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, United States Electronic address
    Lung Cancer 89:76-9. 2015
  6. pmc STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion
    Vivek Subbiah
    Division of Cancer Medicine, Department of Investigational Cancer Therapeutic Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, FC8 3038, Box 0455, Houston, TX, 77030, USA
    J Hematol Oncol 8:66. 2015
  7. pmc Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial
    Vivek Subbiah
    Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 455, Houston 77030, Texas, USA
    J Hematol Oncol 7:52. 2014
  8. pmc Prospects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderly
    Vivek Subbiah
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, Division of Cancer Medicine and Division of Pediatrics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
    Curr Oncol Rep 16:401. 2014
  9. pmc Targeted Therapy of Ewing's Sarcoma
    Vivek Subbiah
    Department of Pediatrics, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Sarcoma 2011:686985. 2011
  10. pmc Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein
    Vivek Subbiah
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, FC8, 3038, Box 0455, Houston, TX 77030, USA
    J Hematol Oncol 7:8. 2014

Detail Information

Publications55

  1. pmc Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures
    Vivek Subbiah
    Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    PLoS ONE 6:e18424. 2011
    ..We performed morphoproteomic profiling to better understand response/resistance mechanisms of Ewing's sarcoma to IGF1R inhibitor-based therapy...
  2. doi request reprint Adolescent oncology: who cares?-the new KID on the block
    Vivek Subbiah
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 87, Houston, TX 77030, USA
    Support Care Cancer 18:771-3. 2010
    ..The need for optimizing and personalizing care in this age group is highlighted...
  3. pmc Gastric adenocarcinoma in children and adolescents
    Vivek Subbiah
    The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Pediatr Blood Cancer 57:524-7. 2011
    ..Initial chemotherapy was mainly platinum-based. Median time to progression was 4 months. The only long-term survivor was a patient with localized disease who had complete surgical removal of primary tumor...
  4. pmc Ewing's sarcoma: overcoming the therapeutic plateau
    Vivek Subbiah
    Department of Investigational Cancer Therapeutics and Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA
    Discov Med 13:405-15. 2012
    ....
  5. pmc Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases
    Vivek Subbiah
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, United States Electronic address
    Lung Cancer 89:76-9. 2015
    ..Our case report forms the first evidence of blood-brain barrier penetration by vandetanib in combination with everolimus. Further research is required in this setting. ..
  6. pmc STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion
    Vivek Subbiah
    Division of Cancer Medicine, Department of Investigational Cancer Therapeutic Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, FC8 3038, Box 0455, Houston, TX, 77030, USA
    J Hematol Oncol 8:66. 2015
    ..To our knowledge, this case represents the first report of clinical response to targeted therapy in a tumor harboring a DCTN1-ALK fusion protein...
  7. pmc Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial
    Vivek Subbiah
    Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 455, Houston 77030, Texas, USA
    J Hematol Oncol 7:52. 2014
    ..The management of this refractory population remains challenging and approximately 400 patients continue to die every year of this refractory disease in the United States...
  8. pmc Prospects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderly
    Vivek Subbiah
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, Division of Cancer Medicine and Division of Pediatrics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
    Curr Oncol Rep 16:401. 2014
    ....
  9. pmc Targeted Therapy of Ewing's Sarcoma
    Vivek Subbiah
    Department of Pediatrics, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Sarcoma 2011:686985. 2011
    ..The successful application of this first-in-class protein-protein inhibitor in the clinic could become a model system for translocation-associated cancers such as EWS...
  10. pmc Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein
    Vivek Subbiah
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, FC8, 3038, Box 0455, Houston, TX 77030, USA
    J Hematol Oncol 7:8. 2014
    ....
  11. pmc Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1)
    Vivek Subbiah
    Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    PLoS ONE 8:e68985. 2013
    ..We performed morphoproteomic profiling of DSRCT (EWS-WT1), Ewing's sarcoma (EWS-FLI1) and Wilms' tumor (WT1) to better understand the signaling pathways for selecting future targeted therapies...
  12. pmc Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist
    Vivek Subbiah
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 455, Houston, Texas 77030, USA
    Mol Cancer Ther 11:2541-6. 2012
    ....
  13. pmc How watching the movie Zombieland helps treatment of cancer in teenagers
    Vivek Subbiah
    Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Cancer Educ 27:188-91. 2012
    ..Communication is the foremost way to keep all doors open in this unique physician-patient relationship. One such approach is "movie therapy" using characters and actions as metaphors for describing cancer and cancer treatment...
  14. ncbi request reprint Insulin-like growth factor 1 receptor (IGF-1R) inhibitor: another arrow in the quiver - Will it hit the moving target?
    Vivek Subbiah
    Expert Opin Investig Drugs 20:1471-7. 2011
    ..Matching patients with these agents based on molecular profiling/signatures will be essential for the proper development of this type of targeted agent...
  15. doi request reprint Phase 1 clinical trials for sarcomas: the cutting edge
    Vivek Subbiah
    Department of Investigational Cancer Therapeutics A Phase I Program, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Curr Opin Oncol 23:352-60. 2011
    ..This review outlines recent phase 1 trials involving sarcoma patients, explores current challenges and highlights future opportunities in sarcoma developmental therapeutics...
  16. doi request reprint Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study
    Jennifer J Wheler
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer Res 76:3690-701. 2016
    ..Cancer Res; 76(13); 3690-701. ©2016 AACR. ..
  17. pmc Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit
    Débora de Melo Gagliato
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, TX Electronic address
    Clin Breast Cancer 14:468-74. 2014
    ..We describe MET mutation and amplification rates in a BC cohort of patients referred to a Phase I Unit...
  18. pmc Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials
    J Andrew Livingston
    Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Oncotarget 7:64421-64430. 2016
    ....
  19. pmc Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies
    Vivek Subbiah
    Department of Investigational Cancer Therapeutics A Phase I Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston 77030, Texas, USA
    Sci Rep 6:35448. 2016
    ..039). Patients with advanced sarcoma treated on phase I clinical trials had a clinical benefit rate of 36% and RMH score predicted survival...
  20. pmc Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion
    Vivek Subbiah
    The University of Texas MD Anderson Cancer Center, Houston, Tex, USA
    Oncology 91:348-353. 2016
    ..Using a CGP database of over 50,000 samples, we identified 11 additional cases that harbor EWSR1-CREB1 and report clinicopathologic characteristics, as these patients may also benefit from such a regimen...
  21. pmc Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials
    Ishwaria M Subbiah
    Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 6:28453-62. 2015
    ..Given the rapid advanced in drug development and emergence of novel agents, we analyzed the characteristics and outcomes of HCC patients treated on early phase trials with an emphasis on targeted therapies...
  22. pmc MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors
    Denis L F Jardim
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas M D Anderson Cancer Center, Houston, TX Electronic address
    Clin Genitourin Cancer 13:e19-26. 2015
    ..The purpose of this study was to determine the prevalence of MET amplification and mutation among GU malignancies and its association with clinical factors and responses to c-MET inhibitors...
  23. pmc Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors
    Yunyun Jiang
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 9:e93676. 2014
    ..Very few somatic mutations have been reported in ES, and none have been identified in DSRCT. The aim of this study is to explore potential actionable mutations in ES and DSRCT...
  24. pmc Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
    Haeseong Park
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 7:67521-67531. 2016
    ..Preliminary anticancer activity was observed in patients with refractory Hodgkin lymphoma, perivascular epithelioid tumor, and hepatocellular carcinoma...
  25. doi request reprint BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Mol Cancer Ther 15:1397-404. 2016
    ..A higher percentage of mutant BRAF(V600) in cfDNA corresponded with shorter OS and in patients receiving BRAF/MEK inhibitors also with shorter TTF. Mol Cancer Ther; 15(6); 1397-404. ©2016 AACR. ..
  26. ncbi request reprint TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics
    Jennifer J Wheler
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Mol Cancer Ther 15:2475-2485. 2016
    ..TP53 alterations may therefore be a ready biomarker for treatment with antiangiogenesis agents, a finding of seminal importance across the cancer field. Mol Cancer Ther; 15(10); 2475-85. ©2016 AACR...
  27. pmc Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit
    Holly Kinahan
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncology 92:14-20. 2017
    ..Due to their aggressive disease and complex comorbid conditions, these patients often need inpatient admission. This study assessed the outcomes of such patients after they were discharged to hospice care...
  28. ncbi request reprint Characteristics and outcomes of patients with gallbladder cancer and cholangiocarcinoma referred to a phase I clinic
    Ishwaria Mohan Subbiah
    Department of Investigational Cancer Therapeutics Phase I Program, University of Texas M D Anderson Cancer Center, Houston, TX Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, Houston, TX Department of Gastrointestinal Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 30:364. 2012
    ..The purpose of this study was to report the presenting characteristics and outcomes of patients with CC and GC treated on phase 1 clinical trials focused on targeted agents at a major cancer center...
  29. pmc FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors
    Denis L Jardim
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 9:e89388. 2014
    ..Preclinical data suggest that FBXW7 mutations sensitize cells to mTOR inhibitors. Clinicopathologic characteristics of cancer patients with FBXW7 mutations and their responses to mTOR inhibitors remain unknown...
  30. pmc MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit
    Denis L Fontes Jardim
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, USA
    Oncotarget 5:1837-45. 2014
    ..In conclusion, MET abnormalities can be found in a small group of patients with GE adenocarcinoma and further studies are necessary to better characterize the prognostic and predictive impact of MET alterations. ..
  31. pmc Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications
    Yunyun Jiang
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 4:884-9. 2013
    ..Our pilot data suggest that PTPRD germline mutations may play a role in the development of Ewing sarcoma, a disease of young people, and their presence may have implications for therapy. ..
  32. pmc Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience
    Ming Mo Hou
    Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Oncotarget 7:35132-43. 2016
    ..Therefore, eligible patients with HG-EOC should be encouraged to participate in novel phase I studies of anti-angiogenic therapies, even after disease progression. ..
  33. ncbi request reprint Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials
    Ishwaria M Subbiah
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 4:153-62. 2013
    ..Patients with advanced cholangiocarcinoma (CC) and gallbladder carcinoma (GC) have few therapeutic options for relapsed disease...
  34. doi request reprint Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic
    Chad Tang
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas
    Clin Cancer Res 20:5956-63. 2014
    ..We hypothesized that chemotherapy synergizes with VEGF/VEGFR (VEGF/R) inhibitors in patients with advanced solid malignancies...
  35. pmc Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms
    Jennifer J Wheler
    Department of Investigational Cancer Therapeutics Phase I Program, The University of Texas MD Anderson Cancer Center, Houston, TX
    Oncotarget 5:2349-54. 2014
    ..The 'molecular individuality' of these tumors suggests that a customized strategy, using an "N-of-One" model of precision medicine, may represent an optimal approach for the treatment of patients with advanced tumors. ..
  36. doi request reprint Neoadjuvant treatment of soft-tissue sarcoma: a multimodality approach
    David Reynoso
    Department of Sarcoma Medical Oncology, M D Anderson Cancer Center, The University of Texas, Houston, Texas 77030, USA
    J Surg Oncol 101:327-33. 2010
    ....
  37. doi request reprint Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials
    Goldy C George
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer 122:3401-3409. 2016
    ..This article describes sleep quality and its relation with fatigue, symptom burden, and mood in patients recruited from an early-phase clinic for targeted therapy...
  38. pmc Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus
    Xiaochun Liu
    Department of Investigational Cancer Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
    Oncotarget 7:23227-38. 2016
    ..In addition, temsirolimus attenuates upregulation of HIF-1α levels, which may be a resistance mechanism for bevacizumab...
  39. doi request reprint Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers
    Muhammad R Khawaja
    Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 0455, Houston, TX, 77030, USA
    Cancer Chemother Pharmacol 77:973-7. 2016
    ..Metformin inhibits mTOR through different mechanisms and may enhance temsirolimus's antitumor activity. We conducted an open-label phase I dose escalation trial of this drug combination in patients with advanced/refractory cancers...
  40. pmc Theranostic Profiling for Actionable Aberrations in Advanced High Risk Osteosarcoma with Aggressive Biology Reveals High Molecular Diversity: The Human Fingerprint Hypothesis
    Daniela Egas-Bejar
    Division of Pediatrics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030
    Oncoscience 1:167-179. 2014
    ..Further large scale analyses of osteosarcoma samples are warranted to test this hypothesis...
  41. ncbi request reprint Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation
    David S Hong
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer Discov 6:1352-1365. 2016
    ..7 months. BRAFV600E circulating cell-free DNA (cfDNA) trends correlated with radiographic changes, and acquired mutations from cfDNA in genes reactivating MAPK signaling were observed at progression...
  42. pmc Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report
    Jennifer Goldstein
    Division of Cancer Medicine, Medical Oncology and Hematology Fellowship Program, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
    BMC Dermatol 15:2. 2015
    ..We describe here a case of a patient with a history of metastatic follicular thyroid carcinoma that we believe developed vandetanib-associated photoallergic dermatitis while enrolled on a phase 1 clinical trial...
  43. pmc Whole abdominopelvic intensity-modulated radiation therapy for desmoplastic small round cell tumor after surgery
    Chelsea C Pinnix
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 83:317-26. 2012
    ..treatment toxicity is of concern. We report our results with whole abdominopelvic intensity-modulated radiation therapy (WAP-IMRT) as a component of multimodality therapy for DSCRT at a single institution...
  44. pmc Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience
    Zhijie Wang
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer Med 5:3437-3444. 2016
    ..Gene aberration-related therapies led to significantly better clinical benefits, supporting that further exploration with novel mechanism-driven therapeutic regimens is warranted...
  45. pmc Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine
    Vivek Subbiah
    Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncotarget 6:40642-54. 2015
    ..We performed comprehensive molecular profiling in two cases of metastatic and chemotherapy-refractory osteosarcoma to guide molecularly targeted therapy...
  46. pmc BRAF mutation testing with a rapid, fully integrated molecular diagnostics system
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncotarget 6:26886-94. 2015
    ..In conclusion, our observations demonstrate that the Idylla test is rapid and has high concordance with other routinely used but more complex BRAF mutation-detecting tests. ..
  47. pmc A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma
    Vivek Subbiah
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
    Oncotarget 5:95-102. 2014
    ..We also expand on the role of rapamycin analogs in oncology. This study supports a role for an immune-type pathogenesis that is amenable to immune modulating targeted therapy in refractory HL...
  48. doi request reprint Ewing's sarcoma: standard and experimental treatment options
    Vivek Subbiah
    Department of Sarcoma Medical Oncology, Division of Cancer Medicine, Labortory of Sarcoma Molecular Therapeutics, M D Anderson Cancer Center, Houston, TX, USA
    Curr Treat Options Oncol 10:126-40. 2009
    ..In this review, we discuss current standard-of-care for patients with Ewing's sarcoma and highlight the most promising experimental therapies in early-phase clinical trials...
  49. pmc Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells
    Chad Tang
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Clin Cancer Res . 2016
    ..Little prospective data are available on clinical outcomes and immune correlates from combination radiation and immunotherapy. We conducted a phase I trial (NCT02239900) testing stereotactic ablative radiotherapy (SABR) with ipilimumab...
  50. pmc Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities
    Denis L Fontes Jardim
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, FC8 3038, Box 0455, Houston, TX 77030, USA
    Orphanet J Rare Dis 8:112. 2013
    ....
  51. doi request reprint 99mTc-sestamibi scan differentiates tumor from other contrast enhancing tissue in choroid plexus tumors
    Vivek Subbiah
    Departments of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Pediatr Hematol Oncol 32:160-2. 2010
    ..Previous literature showed sestamibi to be helpful in detecting residual choroid plexus tumors resulting in further resection. Here, we report the first case to show that sestamibi scans can also help with the opposite decision...
  52. doi request reprint Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab
    Reva K Basho
    Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston
    JAMA Oncol . 2016
    ..While assays to identify mesenchymal TNBC are under development, metaplastic breast cancer serves as a clinically identifiable surrogate to evaluate potential regimens for mesenchymal TNBC...
  53. pmc Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors
    Rashmi S Goswami
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Clin Cancer Res 21:2644-51. 2015
    ..We used a clinical next-generation sequencing (NGS) hotspot mutation panel to investigate clonal evolution in paired primary and metastatic tumors...
  54. doi request reprint Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report
    Jennifer Goldstein
    Division of Cancer Medicine, Medical Oncology and Hematology Fellowship Program, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
    BMC Dermatol 15:22. 2015
    ..We describe here a case of a patient with a history of metastatic follicular thyroid carcinoma that we believe developed vandetanib-associated photoallergic dermatitis while enrolled on a phase 1 clinical trial...
  55. doi request reprint Bilateral gonadoblastoma with dysgerminoma and pilocytic astrocytoma with WT1 GT-IVS9 mutation: A 46 XY phenotypic female with Frasier syndrome
    Vivek Subbiah
    Department of Pediatrics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Pediatr Blood Cancer 53:1349-51. 2009
    ..We present the clinical, radiological, and genetic (WT1 mutation analysis) of a 46 XY phenotypic female with Frasier syndrome with bilateral gonadoblastoma with dysgerminoma who developed pilocytic astrocytoma...